Research Use Disclaimer All information provided here is for educational and informational purposes only
Additionally, if gastrointestinal side effects significantly impact quality of life or prevent adequate nutrition, a medication review may be necessary
Short-acting and prolonged-acting GLP-1 receptor agonists (GLP-1RAs) have been developed
Orders placed on Friday afternoons frequently do not dispatch until Monday, regardless of what the website says about turnaround time
Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
.webp)
